CLINICAL_TRIALS ClinicalTrials.gov record update

Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03999515
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:39:33.840035+00:00
Published At: 2023-09-28T00:00:00+00:00
Record Updated At: 2023-09-28
Results Posted At: 2023-09-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Castration-Resistant Prostate Carcinoma", "Double-Negative Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Stage IV Prostate Cancer AJCC v8", "Stage IVA Prostate Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2023-09-28"
protocolSection.identificationModule.nctId: "NCT03999515"
protocolSection.identificationModule.officialTitle: "Erdafitinib Plus Abiraterone Acetate or Enzalutamide in Double Negative Prostate Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2023-09-28"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.